Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of estrogens in osteoclastogenesis and T-cell immunomodulation
2008-007404-28Phase 4Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of estradiol cypionate, norethindrone and raloxifene in postmenopausal osteoporosis and osteoporosis (2 arms), sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoints: Effect of HRT and raloxifene on osteoclastogenesis, Effect of HRT and raloxifene on T-cell activation and 1 more. Started Mar 2009; status: active.
02
Drugs
estradiol cypionatenorethindroneraloxifene
03
Conditions
postmenopausal osteoporosisosteoporosis
Beyond the preview
Go deeper on 2008-007404-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007404-28.